Chromosome 1q21 abnormalities in multiple myeloma

Area of Science:

• Hematology
• Cancer Genetics
• Cytogenetics

Background:

• Gain of chromosome 1q (+1q) is a frequent cytogenetic abnormality in multiple myeloma (MM), present in ~40% of new cases.
• +1q is often linked to poor prognosis in MM but lacks uniform classification as a high-risk feature.
• Debate persists on whether +1q copy number is critical and if it drives poor outcomes or is a passenger mutation.

Purpose of the Study:

• To review the current understanding of +1q pathogenesis in plasma cell neoplasms.
• To analyze the impact of 1q copy number on MM outcomes.
• To identify potential genetic drivers and clarify the clinical significance of +1q in MM management.

Main Methods:

• Literature review of studies on +1q in multiple myeloma.
• Analysis of proposed pathogenic mechanisms and genetic drivers at the 1q21 locus.
• Evaluation of clinical significance and prognostic impact of +1q copy number.

Main Results:

• While a definitive pathogenic mechanism for +1q remains unclear, several 1q21 genes are implicated in MM progression and therapy resistance.
• The role of +1q as a driver versus a passenger mutation is under investigation.
• +1q may serve as a targetable marker and predict response to novel MM therapies.

Conclusions:

• +1q is a significant cytogenetic abnormality in multiple myeloma with implications for prognosis and treatment.
• Further research into specific genetic drivers within +1q is crucial for targeted therapies.
• Clarifying the role of +1q will refine risk stratification and guide management strategies in MM.